Enhanced protective responses to a serotype-independent pneumococcal vaccine when combined with an inactivated influenza vaccine
© 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society..
Streptococcus pneumoniae and influenza are the world's foremost bacterial and viral respiratory pathogens. We have previously described a γ-irradiated influenza A virus (γ-FLU) vaccine that provides cross-protective immunity against heterosubtypic infections. More recently, we reported a novel non-adjuvanted γ-irradiated S pneumoniae (γ-PN) vaccine that elicits serotype-independent protection. Considering the clinical synergism of both pathogens, combination of a serotype-independent pneumococcal vaccine with a broad-spectrum influenza vaccine to protect against both infections would have a considerable clinical impact. In the present study, we co-immunized C57BL/6 mice intranasally (IN) with a mixture of γ-PN (whole inactivated cells) and γ-FLU (whole inactivated virions) and examined protective efficacy. Co-immunization enhanced γ-PN vaccine efficacy against virulent pneumococcal challenge, which was dependent on CD4+ T-cell responses. In contrast, vaccination with γ-PN alone, co-immunization enhanced pneumococcal-specific effector T-helper 17 cell (Th17) and Th1 memory cell, promoted development of CD4+ tissue-resident memory (TRM) cells and enhanced Pneumococcus-specific antibody responses. Furthermore, co-immunization elicited significant protection against lethal influenza challenge, as well as against co-infection with both influenza and S pneumoniae. This is the first report showing the synergistic effect of combining whole cell and whole virion vaccines to both S pneumoniae and influenza as a single vaccine to protect against individual and co-infection, without compromising pathogen-specific immunity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:131 |
|---|---|
| Enthalten in: |
Clinical science (London, England : 1979) - 131(2017), 2 vom: 01. Jan., Seite 169-180 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Babb, Rachelle [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Co-infection |
|---|
| Anmerkungen: |
Date Completed 06.07.2017 Date Revised 18.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1042/CS20160475 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM266535992 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM266535992 | ||
| 003 | DE-627 | ||
| 005 | 20231224214743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1042/CS20160475 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0888.xml |
| 035 | |a (DE-627)NLM266535992 | ||
| 035 | |a (NLM)27885052 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Babb, Rachelle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhanced protective responses to a serotype-independent pneumococcal vaccine when combined with an inactivated influenza vaccine |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2017 | ||
| 500 | |a Date Revised 18.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society. | ||
| 520 | |a Streptococcus pneumoniae and influenza are the world's foremost bacterial and viral respiratory pathogens. We have previously described a γ-irradiated influenza A virus (γ-FLU) vaccine that provides cross-protective immunity against heterosubtypic infections. More recently, we reported a novel non-adjuvanted γ-irradiated S pneumoniae (γ-PN) vaccine that elicits serotype-independent protection. Considering the clinical synergism of both pathogens, combination of a serotype-independent pneumococcal vaccine with a broad-spectrum influenza vaccine to protect against both infections would have a considerable clinical impact. In the present study, we co-immunized C57BL/6 mice intranasally (IN) with a mixture of γ-PN (whole inactivated cells) and γ-FLU (whole inactivated virions) and examined protective efficacy. Co-immunization enhanced γ-PN vaccine efficacy against virulent pneumococcal challenge, which was dependent on CD4+ T-cell responses. In contrast, vaccination with γ-PN alone, co-immunization enhanced pneumococcal-specific effector T-helper 17 cell (Th17) and Th1 memory cell, promoted development of CD4+ tissue-resident memory (TRM) cells and enhanced Pneumococcus-specific antibody responses. Furthermore, co-immunization elicited significant protection against lethal influenza challenge, as well as against co-infection with both influenza and S pneumoniae. This is the first report showing the synergistic effect of combining whole cell and whole virion vaccines to both S pneumoniae and influenza as a single vaccine to protect against individual and co-infection, without compromising pathogen-specific immunity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Streptococcus pneumoniae | |
| 650 | 4 | |a co-infection | |
| 650 | 4 | |a combination vaccine | |
| 650 | 4 | |a influenza A virus | |
| 650 | 4 | |a protective immunity | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Pneumococcal Vaccines |2 NLM | |
| 700 | 1 | |a Chen, Austen |e verfasserin |4 aut | |
| 700 | 1 | |a Ogunniyi, Abiodun D |e verfasserin |4 aut | |
| 700 | 1 | |a Hirst, Timothy R |e verfasserin |4 aut | |
| 700 | 1 | |a Kara, Ervin E |e verfasserin |4 aut | |
| 700 | 1 | |a McColl, Shaun R |e verfasserin |4 aut | |
| 700 | 1 | |a Alsharifi, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Paton, James C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical science (London, England : 1979) |d 1980 |g 131(2017), 2 vom: 01. Jan., Seite 169-180 |w (DE-627)NLM000401536 |x 1470-8736 |7 nnns |
| 773 | 1 | 8 | |g volume:131 |g year:2017 |g number:2 |g day:01 |g month:01 |g pages:169-180 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1042/CS20160475 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 131 |j 2017 |e 2 |b 01 |c 01 |h 169-180 | ||